Suzan Lazo
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Epigenetics and DNA Methylation, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors(2017)2,436 cited
- → PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer(2018)550 cited
- → Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages(2017)543 cited
- → Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer(2020)210 cited
- → Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.(1998)62 cited
- → Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase(2017)28 cited
- → Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells(2017)18 cited
- → OP01-5 Combination immunotherapy targeting XBP1, CD138 and CS1 with cancer vaccine, checkpoint inhibitors, immune modulator, and epigenetic regulator to treat patients with myeloma or solid tumours: Clinical applications(2023)1 cited
- → Supplementary Table 4 from Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer(2023)